Summary & Overview
CPT 81522: mRNA 12-Gene Breast Cancer Recurrence Risk Score
CPT code 81522 covers an mRNA-based molecular diagnostic test that measures expression of 12 genes and uses an algorithm to generate a breast cancer recurrence risk score. This test informs prognosis and may influence adjuvant treatment planning for patients with early-stage breast cancer. Nationally, availability of validated genomic assays and carrier coverage policies affect access and utilization of such precision oncology services.
Key payers considered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage patterns, typical reimbursement benchmarks, and relevant clinical context for interpreting a 12-gene recurrence score. Readers will find concise benchmarks for coverage and reimbursement, an overview of clinical utility and test methodology, and notes on coding and billing practice for labs and clinicians. The summary also highlights policy updates that commonly affect molecular diagnostic billing and payers’ use of clinical criteria or prior authorization for genomic assays.
This report is intended for laboratory billing teams, oncology clinicians, and health plan policy analysts seeking a national perspective on coding, clinical role, and payer engagement for CPT code 81522. Data not available in the input.
Billing Code Overview
CPT code 81522 describes a laboratory service that performs mRNA gene expression profiling of 12 genes and applies an algorithmic analysis combining patient data with lab results to produce a risk score for breast cancer recurrence. The service type is molecular diagnostic testing with algorithmic risk stratification. The typical site of service is a clinical or reference laboratory that performs specialized molecular assays and computational analysis.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 55-year-old woman with stage I–II, hormone receptor–positive, HER2-negative invasive breast carcinoma undergoes breast-conserving surgery with sentinel lymph node biopsy. The surgical specimen is sent to a molecular diagnostic laboratory for mRNA gene expression profiling to better estimate 10-year risk of distant recurrence and to inform adjuvant systemic therapy decisions. The laboratory technologist extracts RNA from the tumor specimen, measures expression levels of a 12-gene panel using quantitative methods, and combines the analytic results with patient clinical variables (such as tumor size and nodal status) through a validated algorithm to produce a numeric recurrence risk score. The laboratory issues a report to the ordering oncologist and surgeon; results are used during the postoperative oncology visit to discuss the need for chemotherapy in addition to endocrine therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing for the professional interpretation or report only, if separated from the technical lab testing. |
TC | Technical component | Use when billing for the technical component (laboratory processing and testing) only. |